May 26, 2021 9:28 AM 22 seconds read

VistaGen Kick Starts Late-Stage Social Anxiety Disorder Study with PH94B

by Vandana Singh Benzinga Editor
Follow
Comments
  • VistaGen Therapeutics Inc VTGN has initiated its PALISADE Phase 3 study to evaluate PH94B for the acute treatment of Social Anxiety Disorder (SAD).
  • PH94B is an odorless, rapid-onset, investigational pherine nasal spray.
  • PALISADE-1 is being conducted with approximately 200 subjects.
  • Topline results from PALISADE-1 are anticipated in mid-2022.
  • Price Action: VTGN shares are up 1.35% at $3.01 during the premarket session on the last check Wednesday.
VTGN Logo
VTGNVistagen Therapeutics Inc
$2.854.78%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum17.47
Growth6.03
Quality-
Value4.67
Price Trend
Short
Medium
Long
Overview
Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Posted In:
NewsPenny StocksHealth CareSmall CapFDAGeneralanxietyBriefsPhase 3 Trial

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2025 Benzinga | All Rights Reserved